# Pilot study: predicting the interplay between FOXO1 and its downstream long non-coding RNAs in HCC

**Authors:** Rowan Abdelbary, Sherine K. Saber, Fabian Rose, Kai Breuhahn, Shereen A. El Sobky, Injie Omar Fawzy, Ahmed Moustafa, Nada El-Ekiaby, Ahmed Ihab Abdelaziz

PMC · DOI: 10.3389/fonc.2026.1692980 · Frontiers in Oncology · 2026-02-16

## TL;DR

This study identifies 12 long non-coding RNAs potentially regulated by FOXO1, which may play a role in liver cancer development.

## Contribution

The study explores FOXO1's role as an upstream regulator of lncRNAs in HCC, an underexplored area.

## Key findings

- ChIP-Seq data identified 982 lncRNAs possibly regulated by FOXO1.
- RNA sequencing revealed 131 lncRNAs differentially expressed after FOXO1 knockdown.
- Twelve lncRNAs were confirmed as potential downstream targets of FOXO1 in HCC.

## Abstract

Forkhead Box O-1 (FOXO1) is one of the key regulatory transcription factors capable of regulating many critical cellular functions, such as promoting apoptosis and inhibiting cell cycle progression thereby acting as a tumor-suppressor. In hepatocellular carcinoma (HCC), FOXO1 has been shown to be downregulated in liver tissues, and the lower expression has been correlated with poor prognosis. This highlights the necessity of understanding the regulatory functions of FOXO1 in more depth. Various studies have focused on the role of non-coding RNAs (ncRNAs), mainly microRNAs, as upstream regulators of FOXO1 in HCC and how their dysregulation affects carcinogenesis. However, the role of FOXO1 as an upstream regulator of ncRNAs, specifically long non-coding RNAs (lncRNAs), remains an unexplored area of research that needs to be addressed. In this study, we aimed to dissect this interplay and to identify potential FOXO1-regulated lncRNAs which could possibly play a role in the pathogenesis of HCC.

This was achieved through the analysis of publicly available ChIP-Seq data provided by ENCODE database, along with performing RNA sequencing after the knockdown of FOXO1 in Huh-7 cells.

ChIP-Seq data analyses revealed a list of 982 promising lncRNAs that are possibly regulated by FOXO1. Analysis of the RNA sequencing data revealed 131 lncRNAs that were differentially expressed after FOXO1 knockdown. The intersection between ChIP-Seq data and RNA sequencing data showed an overall of 12 lncRNAs that were differentially expressed upon FOXO1 knockdown and also have a FOXO1 binding site in their promoter region, namely ZFAS1, LINC00862, SNHG32, LINC01962, SNHG12, 1QCH-AS1, LINC00324, DCXR-DT, GLUD1P2, FAB5P3, JPX, and SMPD4BP.

In conclusion, 12 lncRNAs were identified as potential downstream targets of FOXO1, suggesting that those lncRNAs could mediate FOXO1 functions in HCC.

## Linked entities

- **Genes:** FOXO1 (forkhead box O1) [NCBI Gene 2308], ZFAS1 (ZNFX1 antisense RNA 1) [NCBI Gene 441951], LINC00862 (long intergenic non-protein coding RNA 862) [NCBI Gene 554279], SNHG32 (small nucleolar RNA host gene 32) [NCBI Gene 50854], LINC01962 (long intergenic non-protein coding RNA 1962) [NCBI Gene 102577426], SNHG12 (small nucleolar RNA host gene 12) [NCBI Gene 85028], LINC00324 (long intergenic non-protein coding RNA 324) [NCBI Gene 284029], DCXR-DT (DCXR divergent transcript) [NCBI Gene 113523640], GLUD1P2 (glutamate dehydrogenase 1 pseudogene 2) [NCBI Gene 414212], JPX (JPX transcript, XIST activator) [NCBI Gene 554203], SMPD4BP (sphingomyelin phosphodiesterase 4B, pseudogene) [NCBI Gene 150776]
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), HCC (MONDO:0007256)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, MIR1269A (microRNA 1269a) [NCBI Gene 100302177] {aka MIR1269, MIRN1269, hsa-mir-1269, hsa-mir-1269a}, MIR183 (microRNA 183) [NCBI Gene 406959] {aka MIRN183, miR-183, miRNA183}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, FOXM1 (forkhead box M1) [NCBI Gene 2305] {aka FKHL16, FOXM1A, FOXM1B, FOXM1C, HFH-11, HFH11}, KDM1A (lysine demethylase 1A) [NCBI Gene 23028] {aka AIMAH3, AOF2, BHC110, CPRF, KDM1, LSD1}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, LINC00324 (long intergenic non-protein coding RNA 324) [NCBI Gene 284029] {aka C17orf44, NCRNA00324, RNA00324, TP53LC03}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323] {aka MMP-14, MMP-X1, MT-MMP, MT-MMP 1, MT1-MMP, MT1MMP}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ZEB1 (zinc finger E-box binding homeobox 1) [NCBI Gene 6935] {aka AREB6, BZP, DELTAEF1, FECD6, NIL2A, PPCD3}, LINC00862 (long intergenic non-protein coding RNA 862) [NCBI Gene 554279] {aka C1orf98, SMIM16}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, ZFAS1 (ZNFX1 antisense RNA 1) [NCBI Gene 441951] {aka C20orf199, HSUP1, HSUP2, NCRNA00275, ZNFX1-AS1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, DCXR-DT (DCXR divergent transcript) [NCBI Gene 113523640], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, MIR3174 (microRNA 3174) [NCBI Gene 100422841], MAP3K11 (mitogen-activated protein kinase kinase kinase 11) [NCBI Gene 4296] {aka MEKK11, MLK-3, MLK3, PTK1, SPRK}, MEG3 (maternally expressed 3) [NCBI Gene 55384] {aka FP504, GTL2, LINC00023, Lnc-DLK1-35, NCRNA00023, PRO0518}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, KL (klotho) [NCBI Gene 9365] {aka HFTC3, KLA}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, DCXR (dicarbonyl and L-xylulose reductase) [NCBI Gene 51181] {aka DCR, HCR2, HCRII, KIDCR, P34H, PNTSU}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, GLUD1P2 (glutamate dehydrogenase 1 pseudogene 2) [NCBI Gene 414212] {aka GLUD1P7, GLUDP2, GLUDP7}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, SOX6 (SRY-box transcription factor 6) [NCBI Gene 55553] {aka HSSOX6, SOXD, TOLCAS}, MMP16 (matrix metallopeptidase 16) [NCBI Gene 4325] {aka C8orf57, MMP-X2, MT-MMP2, MT-MMP3, MT3-MMP}, MDK (midkine) [NCBI Gene 4192] {aka ARAP, MK, NEGF2}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], RCOR1 (REST corepressor 1) [NCBI Gene 23186] {aka COREST, RCOR}, CDKN1B (cyclin dependent kinase inhibitor 1B) [NCBI Gene 1027] {aka CDKN4, KIP1, MEN1B, MEN4, P27KIP1}, LPAR1 (lysophosphatidic acid receptor 1) [NCBI Gene 1902] {aka EDG2, Gpcr26, LPA1, Mrec1.3, VZG1, edg-2}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, SNHG12 (small nucleolar RNA host gene 12) [NCBI Gene 85028] {aka ASLNC04080, C1orf79, LINC00100, LINC001000, NCRNA00100, PNAS-123}, JPX (JPX transcript, XIST activator) [NCBI Gene 554203] {aka DCBALD06, ENOX, LINC00183, NCRNA00183}, AQP9 (aquaporin 9) [NCBI Gene 366] {aka AQP-9, HsT17287, SSC1, T17287}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MIR5188 (microRNA 5188) [NCBI Gene 100847004] {aka mir-5188}
- **Diseases:** lung cancer (MESH:D008175), diabetes (MESH:D003920), Cancer (MESH:D009369), esophageal squamous cell carcinoma (MESH:D000077277), hepatotropic diseases (MESH:D004194), liver diseases (MESH:D008107), osteosarcoma (MESH:D012516), melanoma (MESH:D008545), prostate cancer (MESH:D011471), hyperglycemia (MESH:D006943), cervical cancer (MESH:D002583), metabolic disorders (MESH:D008659), oral squamous cell carcinoma (MESH:D000077195), cervical and gastric cancers (MESH:D013274), carcinogenesis (MESH:D063646), intrahepatic cholangiocarcinoma (MESH:D018281), insulin resistance (MESH:D007333), lung metastasis (MESH:D009362), thyroid cancer (MESH:D013964), colorectal cancer (MESH:D015179), HCC (MESH:D006528), nasopharyngeal carcinoma (MESH:D000077274), invasion (MESH:D009361), triple negative breast cancer (MESH:D064726), breast cancer (MESH:D001943)
- **Chemicals:** polyacrylamide (MESH:C016679), sorafenib (MESH:D000077157), donafenib (MESH:C000710249), fatty acids (MESH:D005227), doxorubicin (MESH:D004317), glucose (MESH:D005947)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G2939A
- **Cell lines:** HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), -F344 — Homo sapiens (Human), Cri du chat syndrome, Finite cell line (CVCL_V767), Huh-7 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_0336), SMMC7721 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0534)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950588/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950588/full.md

## References

76 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950588/full.md

---
Source: https://tomesphere.com/paper/PMC12950588